Hikma Ventures’ Investment In Altoida


Fenwick & West represented Hikma Ventures in the transaction.

Hikma Ventures, the strategic venture capital arm of Hikma Pharmaceuticals PLC, executed an investment in Altoida, Inc. (following the company’s Series A financing round which closed in 2019).

Altoida is a health technology firm with an FDA-cleared and CE Mark-approved medical device and brain health data platform designed to support the early detection of Alzheimer’s disease up to ten years prior to onset.

Altoida plans to utilise the fund to promote its growth and expand its footprint in the US and other global markets including Japan, Brazil, and Europe.

Founded in August 2015, Hikma Ventures invests in emerging companies in the digital health space, globally, that could enhance Hikma’s value proposition, reputation and market intelligence.

The Fenwick transaction team advising Hikma included corporate partner Ian Goldstein (Picture) and associate Alina Azizian, along with intellectual property associate Pinar Bailey.

Involved fees earner: Alina Azizian – Fenwick & West LLP; Pinar Bailey – Fenwick & West LLP; Ian Goldstein – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Hikma Ventures;

Avatar

Author: Ambrogio Visconti